Financial Performance - The company's revenue for Q1 2024 was ¥66,705,459.25, representing a 20.32% increase compared to ¥55,440,064.10 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥14,042,843.67, a 46.66% increase from ¥9,575,298.60 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥12,061,082.58, showing a significant increase of 90.22% from ¥6,340,660.01 in the previous year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.1738, reflecting a 46.67% increase compared to ¥0.1185 in the previous year[5] - The operating profit for the first quarter was CNY 16,305,235.17, up from CNY 11,043,044.54, indicating a growth of 47.5% year-over-year[24] - The total comprehensive income for the first quarter was CNY 14,042,843.67, compared to CNY 9,575,298.60 in the previous year, reflecting a 46.5% increase[25] Cash Flow - The net cash flow from operating activities reached ¥7,445,732.65, a remarkable turnaround from a negative cash flow of ¥632,674.43 in the same quarter last year, marking a 1,276.87% improvement[5] - Cash flow from operating activities generated a net inflow of CNY 7,445,732.65, a significant improvement from a net outflow of CNY -632,674.43 in the previous year[26] - Cash inflow from investment activities totaled CNY 238,619,544.48, down from CNY 404,918,801.08 in the same period last year[26] - Cash outflow for investment activities was CNY 232,351,716.60, compared to CNY 396,288,655.62 in the previous year[27] - The net cash flow from financing activities was CNY -61,366,187.07, indicating cash outflows related to financing[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,002,981,793.10, a decrease of 6.02% from ¥1,067,195,971.50 at the end of the previous year[5] - The total liabilities decreased to RMB 67,390,209.11 from RMB 84,332,557.25, reflecting a reduction of 20.1%[22] - The company’s fixed assets increased to RMB 299,987,910.49 from RMB 236,483,272.86, an increase of 26.8%[21] - Cash and cash equivalents decreased to RMB 286,718,076.27 from RMB 334,370,419.58 at the beginning of the period, a decline of 14.2%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,195[11] - The largest shareholder, Zhang Jun, holds 24.29% of the shares, totaling 19,627,034 shares[11] - The total number of restricted shares at the beginning of the period was 22,775,809, with no shares released or added during the reporting period[14] - The top ten shareholders hold a total of 22,775,809 shares, with the largest shareholder holding 19,627,034 shares[14] - The company has a significant number of shares held by major shareholders, with the largest shareholder, Zhang Jun, holding 19,627,034 shares, representing a substantial portion of the total[14] Strategic Developments - The company plans to establish a wholly-owned subsidiary, Jilin Xinqing Pharmaceutical Technology Co., Ltd., with an investment of RMB 10 million, which has completed the necessary registration procedures[15] - The company received a Supplementary Application Approval Notice from the National Medical Products Administration for its injectable Rosuvastatin Acetate[16] - The company is focused on expanding its market presence through new product approvals and subsidiary establishment[16] - The company is actively pursuing new product development and regulatory approvals to enhance its product portfolio[16] - The company has established a strategic relationship with several investment firms, indicating potential for future capital influx[12] Other Information - The company appointed Ms. Zhang Yinjie as the Vice General Manager and Secretary of the Board, effective from February 1, 2024[15] - The company has not reported any changes in the number of shares lent or returned in the securities lending business during the reporting period[12] - The company repurchased a total of 2,681,558 shares, representing 3.32% of the total share capital, with a total transaction amount of RMB 61,304,621.75[18] - The first quarter report was not audited, as indicated by the company[28]

吉林省西点药业科技发展股份有限公司 审计报告 大华审字[2024]0011006259 号 大 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Da Hua Certified Public Accountants（Special General Partnership） 吉林省西点药业科技发展股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-6 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-73 | 一、审计意见 我们审计了吉林省西点药业科技发 ...

Financial Performance - The company's operating revenue for 2023 was CNY 225,491,234.57, a decrease of 11.73% compared to CNY 255,467,987.43 in 2022[21]. - Net profit attributable to shareholders increased by 24.01% to CNY 50,502,418.80 in 2023, up from CNY 40,723,025.38 in 2022[21]. - The net profit after deducting non-recurring gains and losses was CNY 28,361,905.28, down 15.67% from CNY 33,633,860.81 in 2022[21]. - The total assets at the end of 2023 reached CNY 1,067,195,971.50, reflecting a growth of 4.94% from CNY 1,017,003,454.64 at the end of 2022[21]. - The basic earnings per share increased by 18.84% to CNY 0.6250 in 2023, compared to CNY 0.5259 in 2022[21]. - The company's total revenue for 2023 was ¥225,491,234.57, representing a year-over-year decrease of 11.73%[58]. - The net profit attributable to shareholders for 2023 was ¥50,502,418.80, showing a year-over-year increase of 24.01%[58]. - The main pharmaceutical business contributed ¥225,141,192.09, accounting for 99.84% of total revenue, with a year-on-year decline of 11.85%[82]. - The revenue from the compound ferrous sulfate folic acid tablets was ¥116,064,612.30, representing 51.47% of total revenue, down 8.93% from the previous year[82]. Dividend Policy - The company plans to distribute a cash dividend of 2.60 RMB per 10 shares (including tax) to all shareholders[3]. - The total distributable profit for the company is 375,727,232.01 RMB, with cash dividends accounting for 100% of the profit distribution[188]. - The company has a stable profit distribution policy, prioritizing cash dividends while considering sustainable development[187]. - The company is in a mature development stage and aims to maintain a minimum of 40% cash dividend ratio during profit distribution[189]. - The company has no plans for stock dividends or bonus shares in the current profit distribution[190]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing sector, focusing on the research, development, production, and sales of chemical drugs[31]. - The company has a focus on developing new products and technologies in the pharmaceutical sector[3]. - The company aims to become a competitive player in the domestic blood supplement and mental disorder medication markets, leveraging its integrated advantages in "raw materials + formulations"[50]. - The company is actively involved in the transformation and upgrading of the pharmaceutical industry, ensuring the safety and quality of drug operations and usage[49]. - The company is focused on ethical standards in scientific research, aligning with new regulations that promote comprehensive oversight in the field[49]. Research and Development - The company is focused on research and development, collaborating with academic institutions to accelerate product pipeline development[53]. - The company has 22 registered formulations and 16 active pharmaceutical ingredient (API) registrations, focusing on areas such as anemia treatment and psychiatric disorders[51]. - The company is actively developing new products, including protein succinate iron and risperidone orally disintegrating tablets, which are currently in the review stage[59]. - The company has initiated two new drug research projects based on the efficacy of Rhizoma Alismatis in treating complications related to diabetes and lymphatic obstruction[70]. - The company is committed to continuous R&D investment to create differentiated barriers and enhance its ability to withstand market risks[76]. Compliance and Governance - The company emphasizes compliance with new regulations and standards in the pharmaceutical industry, which are expected to enhance quality management and oversight throughout the drug lifecycle[48]. - The company has established a robust internal control system to enhance governance and ensure compliance with relevant laws and regulations[143]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards and enhancing decision-making processes[145]. - The company has a supervisory board consisting of 5 members, including 2 employee supervisors, complying with legal requirements[146]. - The company is focused on maintaining compliance and transparency in its governance practices[165]. Risk Management - The company emphasizes potential risks including policy risks from pharmaceutical system reforms and fluctuations in raw material prices[3]. - The company is facing policy risks due to ongoing medical system reforms, which may increase operational costs and alter business models if not adapted timely[135]. - Fluctuations in raw material prices pose risks to the company's profit margins, and it is focusing on R&D of raw materials to control costs[138]. - The company adopts a cautious approach to drug development, prioritizing projects with thorough market research to mitigate risks associated with high costs and low success rates[139]. Environmental Responsibility - The company has highlighted its commitment to environmental protection and social responsibility in its annual report[5]. - The company must comply with multiple environmental protection laws and standards, including the Water Pollution Prevention and Control Law and the Air Pollution Prevention and Control Standards[200]. - The company generates pollutants such as waste gas, wastewater, noise, and solid waste during its production operations[200]. - The company adheres to specific guidelines for self-monitoring and pollution control in the pharmaceutical industry[200]. Human Resources - The company has a total of 269 employees, with 118 in production, 70 in sales, 49 in technical roles, 10 in finance, 22 in administration[180]. - The company has conducted extensive training programs for employees, covering various aspects of quality management and compliance with GMP regulations[183][184]. - The number of R&D personnel decreased by 2.00% to 49 in 2023, with their proportion of total staff remaining relatively stable at 18.22%[97]. Financial Management - The company reported a significant increase in cash and cash equivalents, rising to 334,370,419.58, which is 31.33% of total assets, up from 19.94% at the beginning of the year[103]. - The company has a cash management balance of RMB 120 million, with RMB 116.30 million held in a special account for raised funds[117]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 2.2854 million CNY[167]. - The company is actively involved in the management of its remuneration policies through a dedicated compensation and assessment committee[166]. Corporate Changes - The company held a shareholder meeting on August 3, 2023, to elect a new board of directors and supervisory board[156]. - Several directors, including Ding Shiguo, Wang Baozhong, and Liu Yanbin, completed their terms and left their positions on August 3, 2023[157]. - The company appointed new members to the eighth board of directors and supervisory board following the recent elections[156]. - The financial director Meng Si was appointed on August 3, 2023, indicating a leadership change in the financial management team[162][163].

证券代码：301130 证券简称：西点药业 公告编号：2024-052 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 吉林省西点药业科技发展股份有限公司董事会 关于 2023 年年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》和深圳证券交易所颁布的《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关规定，现将吉林省西点药 业科技发展股份有限公司（以下简称"公司"）2023 年年度募集资金存放与使 用情况报告如下： 经中国证券监督管理委员会《关于同意吉林省西点药业科技发展股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕5号）同意注册，吉林省 西点药业科技发展股份有限公司（以下简称"公司"或"本公司"）首次公开发 行人民币普通股（A股）股票2,020.0986万股，每股面值1元，每股发行价格为人 民币22.55元，募集资金总额为人民币45,553.22万元，扣除各类发行费用后 ...

吉林省西点药业科技发展股份有限公司 2023 年度独立董事述职报告 二、2023 年度履职概况 一、独立董事基本情况 本人苏冰，1964 年 2 月出生，本科学历，研究员职称。历任白求恩医科大 学制药厂技术员、质量部部长。自 2020 年 4 月至今，任公司独立董事。 任职期间，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况，并已向公司提交 2023 年度独立性自查报 告，确认符合任职的独立性要求。 2023 年度独立董事述职报告 报告期间，本人认真参加了公司召开的董事会、股东大会、董事会专门委 员会，履行了独立董事的义务，认为 2023 年度公司董事会、股东大会的召集召 开符合法定程序，重大经营决策事项和其他重大事项均履行了相关程序，合法 有效。对提交董事会和股东大会的全部议案进行了认真审议。本人出席会议的 情况如下： 本人苏冰作为吉林省西点药业科技发展股份有限公司的独立董事，严格按 照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》《公司章程》《独立董 ...

吉林省西点药业科技发展股份有限公司 2023 年度独立董事述职报告 2023 年度独立董事述职报告 各位股东及股东代表： 本人张士宇历任吉林省西点药业科技发展股份有限公司（以下简称"公司"） 第七届董事会独立董事，于 2023 年 8 月 3 日任期届满离任。任职期间本人严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《上市公司治理准则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《公司章程》及《独立董事工作制度》等法律法规、规范性文件的相关规定和要 求，诚实、勤勉、独立履行职责，积极关注和参与研究公司的发展，促进公司规 范运作，充分发挥独立董事的独立性和专业性作用，切实维护了公司和股东的利 益，现将 2023 年度履职情况报告如下： 一、独立董事基本情况 本人拥有专业资质及能力，在从事的专业领域积累了丰富的经验。本人个 人工作履历、专业背景等相关情况如下： 张士宇，1977 年 9 月生，本科学历，现任上海市锦天城（长春）律师事务 所律师/合伙人，曾先后在吉林省高级人民法院、上海博恩律师事务所、吉林佳 禾律师事务所、吉林宇中人律师事务所、吉林司鼎律师事务所等单位工 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301130 证券简称：西点药业 公告编号：2024-047 吉林省西点药业科技发展股份有限公司 第八届监事会第六次会议决议公告 （二）审议通过《关于公司<2023 年年度报告>全文及其摘要的议案》 一、会议召开情况 吉林省西点药业科技发展股份有限公司（以下简称"公司"）第八届监事会 第六次会议于 2024 年 4 月 22 日 10:30 在长春市卫星路 1471 号公司会议室以现 场结合通讯方式召开。本次会议通知于 2024 年 4 月 12 日以邮件、电话、书面等 方式送达全体监事。会议由监事会主席侯雨霖先生主持，应出席监事 5 名，实际 出席监事 5 名，其中监事潘贤平、马端香以通讯方式参会并表决。 公司董事会秘书、保荐代表人列席了会议。 会议的召开符合《中华人民共和国公司法》和《公司章程》的规定，会议合 法有效。 二、会议审议情况 经与会监事认真审议并表决，一致通过了如下事项： （一）审议通过《关于公司<2023 年度监事会工作报告>的议案》 根据公司监事会 2023 年度工作情况，监事会作出 ...

证券代码：301130 证券简称：西点药业 公告编号：2024-050 吉林省西点药业科技发展股份有限公司 根据公司《首次公开发行股票并在创业板上市招股说明书》，公司首次公开 发行人民币普通股（A股）股票的募集资金在扣除发行费用后将投资于以下项目： 单位：万元 | 序 | 项目名称 | 总投资额 | 拟投入募集资金 | | --- | --- | --- | --- | | 号 | | | | | 1 | 综合固体制剂车间建设项目 | 10,576.38 | 10,576.38 | | 2 | 中药现代化提取车间建设项目 | 8,009.38 | 8,009.38 | | 3 | 草酸艾司西酞普兰原料药生产项目 | 5,350.19 | 5,350.19 | | 4 | 研发中心建设项目 | 5,004.64 | 5,004.64 | | 5 | 营销网络建设项目 | 5,200.00 | 5,200.00 | | | 合计 | 34,140.59 | 34,140.59 | 关于部分募投项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 吉林省西 ...

吉林省西点药业科技发展股份有限公司 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 内部控制审计报告 大华内字[2024]0011000172 号 吉林省西点药业科技发展股份有限公司 内部控制审计报告 （截止 2023 年 12 月 31 日） 目 录 页 次 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 内 部 控 制 审 计 报 告 大华内字[2024]0011000172 号 吉林省西点药业科技发展股份有限公司全体股东： 一、 内部控制审计报告 1-2 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 第 ...

吉林省西点药业科技发展股份有限公司 2023 年度财务决算报告 2023 年度财务决算报告 吉林省西点药业科技发展股份有限公司（以下简称"公司"）2023 年财务决算工作已 完成，财务会计报告按照《企业会计准则》的规定编制，大华会计师事务所（特殊普通合 伙）出具了标准无保留意见的审计报告大华审字[2024]0011006259 号，现将有关财务决算 情况简要汇报如下，详细情况请参阅公司年度报告中的财务报告部分。 一、财务状况 | | | | 单位：元 | | --- | --- | --- | --- | | 项目 | 2023 年 12 月 31 日 | 2022 年 12 月 31 日 | 增减变动幅 | | | | | 度 | | 资产总计 | 1,067,195,971.50 | 1,017,003,454.64 | 4.94% | | 流动资产合计 | 633,763,286.10 | 704,172,417.08 | -10.00% | | 非流动资产合计 | 433,432,685.40 | 312,831,037.56 | 38.55% | | 负债合计 | 84,332,557.25 | 7 ...